Recent Updates
Recently added Catalysts
ATYR Positive Sentiment

Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis

Wednesday, October 2, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the efficacy of therapeutic doses of Efzofitimod in treating pulmonary sarcoidosis. The results indicate a significant positive impact on patient outcomes, suggesting that Efzofitimod may be a viable treatment option. This development could enhance the management of pulmonary sarcoidosis and improve patients' quality of life.
Price reaction · baseline $1.72 (2024-10-01 close) · hit pre-market · clean, no other ATYR news in the window
day 0 close · peak
+3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Efzofitimod shows promising efficacy in treating pulmonary sarcoidosis.
  • Therapeutic doses have demonstrated significant positive outcomes.
  • The treatment could improve the quality of life for patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
5.7%
average across 7 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kg
Phase 3 · Pulmonary Sarcoidosis

Full Press Release Details

• Company About Us Leadership Team Board of Directors Advisors Contact
• Our Science Extracellular t RNA Synthetase Biology Intellectual Property Publications, Posters and Presentations
• R&D Pipeline Efzofitimod Research Programs Pangu
• Patients Clinical Trials About Pulmonary Sarcoidosis About SSc-ILD EFZO-CONNECT ™ Expanded Access Policy
• Careers Working at aTyr Career Opportunities
• Investors and Media Corporate Governance Board of Directors Board Committees News Releases SEC Filings Stock Information Analyst Coverage Investor Alerts Events and Webcasts Media
• Privacy Policy
• About Us
• Leadership Team
• Board of Directors
• Advisors
• Contact
• Extracellular t RNA Synthetase Biology
• Intellectual Property
• Publications, Posters and Presentations
• Pipeline
• Efzofitimod
• Research Programs
• Pangu
• Clinical Trials
• About Pulmonary Sarcoidosis
• About SSc-ILD
• EFZO-CONNECT ™
• Expanded Access Policy
• Working at aTyr
• Career Opportunities
• Corporate Governance Board of Directors Board Committees
• News Releases
• SEC Filings
• Stock Information
• Analyst Coverage
• Investor Alerts
• Events and Webcasts
• Media
• Board of Directors
• Board Committees

Frequently Asked Questions

What is Efzofitimod?

Efzofitimod is a therapeutic agent being studied for its efficacy in treating pulmonary sarcoidosis.

What condition does Efzofitimod target?

Efzofitimod specifically targets pulmonary sarcoidosis.

What were the results of the Efzofitimod trials?

The trials showed significant positive outcomes for patients receiving therapeutic doses of Efzofitimod.

How could Efzofitimod benefit patients?

Efzofitimod may improve the quality of life for patients suffering from pulmonary sarcoidosis.

ShareAdd on Google
Tags: ATYR Viatris Investor Conferences Healthcare Efzofitimod pulmonary sarcoidosis aTyr clinical trials therapeutic doses
Last updated: Oct 2, 2024

Biotech snapshot

Cash runway
$57M liquidity · $3M/mo burn
~18 mo
Low dilution risk
Lead asset
Efzofitimod/kgPhase 3
Pulmonary Sarcoidosis →

Catalyst track record

+41%
best trade around ATYR's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ATYR.

See every catalyst's timing & PoA →